Video
Dr. Murray on real-world study of antegrade administration of reverse thermal mitomycin gel for UTUC
Author(s):
Video Player is loading.
Katie Murray, DO, urologic oncologist and assistant professor of Urology at the University of Missouri, discusses findings from a real-world study of antegrade administration of reverse thermal mitomycin gel (Jelmyto) for primary chemoablation of upper tract urothelial carcinoma via percutaneous nephrostomy tube. The study, which was presented at the 2022 AUA Annual Meeting (abstract PD58-06), sought to analyze whether antegrade administration of Jelmyto might decrease some of the comorbidity and complications reported in the pivotal OLYMPUS trial that led to the FDA approval of the treatment.
Related Videos
5 key trial insights from AUA 2025
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Related Content
